COMPASS Pathways Plc American Depository Shares (CMPS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, COMPASS Pathways Plc American Depository Shares (NASDAQ: CMPS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $8.41 (-27.31% 1D, market cap $1.60B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CMPS ranks #456 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMPS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and MLYS (Mineralys Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.4%, cap $1.61B). Among the 5-stock peer group, CMPS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
Per CMPS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816590), COMPASS Pathways Plc American Depository Shares generated $501.3M in revenue (+0.5% YoY), -$269.8M in net income, and -$157.2M in free cash flow against $210.3M in total assets and $14.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CMPS currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.83) and Max Pain ($8.83) forces dealer call-delta covering toward $16.66.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
COMPASS Pathways Plc American Depository Shares (CMPS) dropped -27.31% to $8.41, trading at 32% of its 52-week range ($4.88 – $15.87). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present.
LONDON & JERSEY CITY, N.J., November 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depr
An accelerated FDA review could benefit Compass Pathways.
The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
COMPASS Pathways (CMPS) drew fresh attention after confirming a prominent role at the 2026 NEI Fall Congress, highlighting its COMP360 psilocybin program and an educational initiative focused on treatment-resistant depre
LONDON & JERSEY CITY, N.J., October 28, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participa
Compass Pathways is initially targeting the TRD market, which is large and underserved. Find out why CMPS stock is a Buy.
LONDON & JERSEY CITY, N.J., October 27, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will
Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026. Helu
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMPS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMPS. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, COMPASS Pathways Plc American Depository Shares (CMPS) ranks #456 by composite RQD confidence (40/100, grade D-) and #290 by equity capitalization ($1.60B). Within this direct 5-issuer industry benchmark cohort, CMPS leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. NBTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with CMPS at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMPS
ACTIVE
COMPASS Pathways Plc American Depository Shares | D- | 40/100 | — | — | -35.0% | -27.31% | $1.60B | Benchmark Subject |
| URGN UroGen Pharma Ltd. | E | 24/100 | — | 88.7% | -35.0% | +5.01% | $1.60B | /urgn-vs-cmps → |
| MLYS Mineralys Therapeutics Inc. | E | 33/100 | — | — | -28.4% | -14.47% | $1.61B | /mlys-vs-cmps → |
| NBTX Nanobiotix S.A. | D | 49/100 | — | — | — | -10.39% | $1.59B | /nbtx-vs-cmps → |
| RARE Ultragenyx Pharmaceutical Inc. | E | 23/100 | — | — | -35.0% | +1.24% | $1.59B | /rare-vs-cmps → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported GAAP revenue of $501.3M (+0.5% vs. FY2024 revenue of $499.0M , and +30.8% cumulative change since FY2023) , GAAP net income of -$269.8M, operating cash flow of -$157.2M, and free cash flow of -$157.2M (-31.9% YoY). On the balance sheet, CMPS closed FY2025 with $210.3M in total assets against $14.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $501.3M | -$269.8M | -$157.2M | -$157.2M | $210.3M | $14.1M |
| FY2024 (FY) | 2024-12-31 | $499.0M | -$155.1M | -$119.2M | -$119.2M | $213.7M | $24.7M |
| FY2023 (FY) | 2023-12-31 | $383.4M | -$118.5M | -$97.4M | -$97.4M | — | — |
As of 2026-11-03, COMPASS Pathways Plc American Depository Shares (NASDAQ: CMPS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $8.41 (-27.31% 1D, market cap $1.60B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CMPS ranks #456 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMPS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and MLYS (Mineralys Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.4%, cap $1.61B). Among the 5-stock peer group, CMPS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
Per CMPS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816590), COMPASS Pathways Plc American Depository Shares generated $501.3M in revenue (+0.5% YoY), -$269.8M in net income, and -$157.2M in free cash flow against $210.3M in total assets and $14.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CMPS last traded at $8.41 (-27.31% on volume of 16,850,617 shares), positioning the stock -34.45% below its 50-day simple moving average ($12.83) and -19.52% below its 200-day simple moving average ($10.45). Across its 52-week range of $4.88 to $15.87, CMPS sits at the 32.1% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($7.52 to $9.30).
COMPASS Pathways Plc American Depository Shares (CMPS) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $8.41 (-27.31% 1D, market capitalization $1.60B).
COMPASS Pathways Plc American Depository Shares is listed on NASDAQ under the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The financials report revenue of — for each reported period, .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported $501.3M in annual revenue (up from $499.0M in FY2024, +0.5% YoY) and -$269.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($383.4M revenue, -$118.5M net income) through FY2025, CMPS scaled operating cash flow to -$157.2M and free cash flow to -$157.2M, backed by $210.3M in total assets against $14.1M in total debt.
Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.
Real-time company headlines, analyst actions, and sector developments for COMPASS Pathways Plc American Depository Shares (CMPS) • Click "Debate This Headline" to argue it in the Roar Pit below
According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present.
LONDON & JERSEY CITY, N.J., November 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depr
An accelerated FDA review could benefit Compass Pathways.
The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
COMPASS Pathways (CMPS) drew fresh attention after confirming a prominent role at the 2026 NEI Fall Congress, highlighting its COMP360 psilocybin program and an educational initiative focused on treatment-resistant depre
LONDON & JERSEY CITY, N.J., October 28, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participa
Compass Pathways is initially targeting the TRD market, which is large and underserved. Find out why CMPS stock is a Buy.
Reported cash of $149.6M and debt of $14.1M in FY 2025 indicate a balance sheet with more cash than debt, supported by a Debt/Equity of 0.5.. When you look under the hood at CMPS, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $15.87. My 12M target is $14.00.
@MidwestValue Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.57 and keeping dry powder in case we test $10.76.
Here is the bear case nobody on the bull side wants to address on CMPS: Net income of -$269.8M in FY 2025 against FCF of -$157.2M, a ROIC of -35%, and an FCF yield of -9.31% show sustained cash consumption with no reported revenue.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).